| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1)(2) |
Consolidated | ||||||
| For the three months ended June 30, 2021 | ||||||||||||
| Revenues | 10,032 |
17,544 |
23,268 |
50,844 |
(131) |
50,713 |
||||||
| Segment (adj) EBITDA | 3,129 |
4,519 |
1,850 |
9,498 |
(2,572) |
6,925 |
||||||
| Segment (adj) EBITDA % | 31.2% |
25.8% |
7.9% |
18.7% |
13.7% |
|||||||
| For the three months ended June 30, 2020 | ||||||||||||
| Revenues | 9,540 |
11,735 |
16,777 |
38,052 |
65 |
38,117 |
||||||
| Segment (adj) EBITDA | 3,756 |
1,139 |
650 |
5,546 |
(2,164) |
3,382 |
||||||
| Segment (adj) EBITDA % | 39.4% |
9.7% |
3.9% |
14.6% |
8.9% |
|||||||
| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1)(2) |
Consolidated | ||||||
| For the six months ended June 30, 2021 | ||||||||||||
| Revenues | 20,251 |
33,776 |
42,381 |
96,408 |
(142) |
96,266 |
||||||
| Segment (adj) EBITDA | 6,558 |
9,060 |
1,706 |
17,324 |
(5,059) |
12,265 |
||||||
| Segment (adj) EBITDA % | 32.4% |
26.8% |
4.0% |
18.0% |
12.7% |
|||||||
| For the six months ended June 30, 2020 | ||||||||||||
| Revenues | 19,361 |
27,380 |
37,592 |
84,333 |
29 |
84,362 |
||||||
| Segment (adj) EBITDA | 6,401 |
3,595 |
1,768 |
11,765 |
(4,780) |
6,985 |
||||||
| Segment (adj) EBITDA % | 33.1% |
13.1% |
4.7% |
14.0% |
8.3% |
| (1) Unallocated Revenues consists of occasional one-off sales in our core competencies not allocated to any of our segments. |
| (2) Unallocated segment adjusted EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
